Why the study?
Does ticagrelor reduce ischemic events compared to clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention?
Does ticagrelor reduce ischemic events compared to clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention?
Ticagrelor is superior to clopidogrel for reducing ischemic events without increasing major bleeding in ACS patients undergoing complex PCI.
Association may favor ticagrelor in complex PCI; hypothesis-generating and requires randomized confirmation before practice change.
Whilst the risk of major bleeding was comparable between the two drugs, ticagrelor was associated with a significantly lower risk of ischemic events than clopidogrel in ACS patients undergoing complex PCI.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: